Previous research has unveiled several roles of CS-6 in different cancers, including its inhibits IKKβ phosphorylation by targeting ATP binding sites, thereby inhibiting NF-κB binding and p300 recruitment of COX-2 promoters, thereby strongly inhibiting COX-2 expression in lung cancer (Lan et al., 2020). Here, EP300 is linked to lung cancer.